JP2021508687A - Vegfアンタゴニストを含む液体組成物 - Google Patents
Vegfアンタゴニストを含む液体組成物 Download PDFInfo
- Publication number
- JP2021508687A JP2021508687A JP2020534166A JP2020534166A JP2021508687A JP 2021508687 A JP2021508687 A JP 2021508687A JP 2020534166 A JP2020534166 A JP 2020534166A JP 2020534166 A JP2020534166 A JP 2020534166A JP 2021508687 A JP2021508687 A JP 2021508687A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- composition according
- protein
- sucrose
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 125
- 239000007788 liquid Substances 0.000 title claims abstract description 69
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims description 18
- 239000005557 antagonist Substances 0.000 title claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 239000003381 stabilizer Substances 0.000 claims abstract description 44
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 31
- 229930006000 Sucrose Natural products 0.000 claims abstract description 31
- 239000005720 sucrose Substances 0.000 claims abstract description 31
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 24
- 229930195725 Mannitol Natural products 0.000 claims abstract description 24
- 239000000594 mannitol Substances 0.000 claims abstract description 24
- 235000010355 mannitol Nutrition 0.000 claims abstract description 24
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 22
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 22
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- 108010081667 aflibercept Proteins 0.000 claims description 18
- 239000007853 buffer solution Substances 0.000 claims description 17
- 229960002833 aflibercept Drugs 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 239000001488 sodium phosphate Substances 0.000 claims description 12
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 12
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 13
- 239000000872 buffer Substances 0.000 abstract description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
- 239000011734 sodium Substances 0.000 abstract description 3
- 229910052708 sodium Inorganic materials 0.000 abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 abstract 3
- 235000014304 histidine Nutrition 0.000 abstract 1
- 150000002411 histidines Chemical class 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 abstract 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 15
- 238000003860 storage Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000008121 dextrose Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000058223 human VEGFA Human genes 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 229940051306 eylea Drugs 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 101150048336 Flt1 gene Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 101710165315 Sialidase A Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000012906 subvisible particle Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
リン酸ナトリウム、ヒスチジン、又はそれらの組合せを含む緩衝液、及び
塩化ナトリウムを含まない、かつ/又はトレハロース、スクロース、マンニトール及びそれらの組合せからなる群から選択される少なくとも1つを含む、安定剤。
(1)5mg/ml〜100mg/mlのタンパク質;
(2)pH4〜8の緩衝液;及び
(3)安定剤、
ここで、緩衝液はリン酸ナトリウム、ヒスチジン、又はそれらの組合せを含み、
かつ、安定剤は塩化ナトリウムを含まない、かつ/又はトレハロース、スクロース及びマンニトールからなる群から選択される少なくとも1つを含む。
液体組成物は、界面活性剤を、例えば、全組成物に基づいて0.01〜3%(w/v)の量でさらに含んでもよい。
(1)タンパク質;
(2)リン酸ナトリウム、ヒスチジン又はそれらの組合せを含む緩衝液;及び
(3)塩化ナトリウムを含まない、かつ/又はトレハロース、スクロース、及びマンニトールからなる群から選択される1以上を含む、安定剤。
SDTGRPFVEM YSEIPEIIHM TEGRELVIPC RVTSPNITVT LKKFPLDTLI PDGKRIIWDS RKGFIISNAT YKEIGLLTCE ATVNGHLYKT NYLTHRQTNT IIDVVLSPSH GIELSVGEKL VLNCTARTEL NVGIDFNWEY PSSKHQHKKL VNRDLKTQSG SEMKKFLSTL TIDGVTRSDQ GLYTCAASSG LMTKKNSTFV RVHEKDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G
(ジスルフィド架橋:30−79;124−185;246−306;352−410、二量体:211;214)
(1)タンパク質;
(2)リン酸ナトリウム、ヒスチジン、又はそれらの組合せを含む緩衝液;
(3)塩化ナトリウムを含まない、かつ/又はトレハロース、スクロース及びマンニトールからなる群から選択される1以上を含む、安定剤;そして
(4)任意で、界面活性剤。
VEFGアンタゴニストとして機能する融合タンパク質である、タンパク質薬物としてのアフリベルセプト(ヒトVEGF受容体1及び2の細胞外ドメインに由来するVEGF結合部位とヒトIgG1のFc領域の融合タンパク質;CAS番号:862111−32−8;配列番号1)を用いて、タンパク質薬物の液体組成物1〜14を、以下の表2の組成物として調製した:
実施例1で調製した組成物1〜14の安定性を試験するために、組成物中のタンパク質薬物の凝集度を示す%HMW(%高分子量;重量に基づく)を、タンパク質薬剤濃度40mg/mL、pH6.2、40℃の条件で4週間の貯蔵の最中にSE−HPLCで測定した。
表5に示すように、組成物1−10(タンパク質薬物濃度:40mg/mL;pH6.2;界面活性剤:0.03%(w/v)PS20)を、優れた安定化効果が実施例1及び表3で確認された安定剤としてのマンニトール、スクロース、又はトレハロースを用いて、及び対照の安定剤としてのデキストロースを用いて、調製した。これらの組成物の安定性をテストするために、組成物中のタンパク質薬物の変性度を示す%酸性(%酸性バリアント含有量;重量に基づく)及び%メイン(電荷バリアントアスペクトの初期状態の表面電荷を維持するタンパク質の含有量(重量に基づく))を、40℃で4週間貯蔵中に、画像化キャピラリー等電点電気泳動(icIEF)を用いて測定した。
実施例1で調製した表2の組成物1〜14中の薬理活性成分であるアフリベルセプトの活性の維持を試験するために、VEFGに対する組成物中のアフリベルセプトの%RBA(相対結合活性)及び%RPA(相対効力活性)を、タンパク質薬物濃度40mg/mL、pH6.2、40℃の条件で4週間貯蔵の最中に測定した。
実施例1で調製した組成物のうち、実施例2〜4で優れた安定性が確認された6種類の組成物(表2における組成物4、5、6、8、9及び10)の%メインを、CE−SDS(キャピラリー電気泳動ドデシル硫酸ナトリウム)を用いて測定した(40℃、4週間)。
Claims (28)
- 以下を含む液体組成物:
(1)5mg/ml〜100mg/mlのタンパク質;
(2)pH4〜8の緩衝液;及び
(3)安定剤、
であって、前記緩衝液は、リン酸、酢酸、クエン酸、コハク酸、前記酸の薬学的に許容される塩、及びヒスチジンからなる群から選択される少なくとも1つを含み、
かつ前記安定剤は、塩化ナトリウムを含まない、液体組成物。 - 前記安定剤が、トレハロース、スクロース、及びマンニトールからなる群から選択される少なくとも1つを含む、請求項1に記載の液体組成物。
- 前記タンパク質の量が、20mg/ml〜60mg/mlである、請求項1に記載の液体組成物。
- 前記緩衝液のpHが、5.2〜7.2である、請求項1に記載の液体組成物。
- 前記組成物中の緩衝液の濃度が、1〜50mMである、請求項1に記載の液体組成物。
- 前記組成物中の緩衝液の濃度が、1〜20mMである、請求項5に記載の液体組成物。
- 前記安定剤が、1〜20%(w/v)トレハロース、1〜20%(w/v)スクロース、及び0.5〜10%(w/v)マンニトールからなる群から選択される少なくとも1つを含む、請求項2に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)トレハロース、5〜12%(w/v)スクロース、及び2〜7%(w/v)マンニトールからなる群から選択される少なくとも1つを含む、請求項7に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)スクロースを含む、請求項8に記載の液体組成物。
- 前記緩衝液が、1〜20mMリン酸ナトリウムを含む、請求項1に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)トレハロース、5〜12%(w/v)スクロース、及び2〜7%(w/v)マンニトールからなる群から選択される少なくとも1つを含む、請求項10に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)スクロースを含む、請求項11に記載の液体組成物。
- 前記緩衝液が、1〜20mMのヒスチジンを含む、請求項1に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)トレハロース、5〜12%(w/v)スクロース、及び2〜7%(w/v)マンニトールからなる群から選択される少なくとも1つを含む、請求項13に記載の液体組成物。
- 前記安定剤が、5〜12%(w/v)スクロースを含む、請求項14に記載の液体組成物。
- 界面活性剤をさらに含む、請求項1に記載の液体組成物。
- 前記界面活性剤が、全組成物に基づいて、0.001〜3%(w/v)の量で含まれる、請求項16に記載の液体組成物。
- 水性かつ等張性である、請求項1に記載の液体組成物。
- 前記組成物が、水性であり、かつ200〜400mOsm/kgの浸透圧を有する、請求項1に記載の液体組成物。
- 前記タンパク質が、10〜500kDaの分子量を有する、請求項1〜19のいずれか一項に記載の液体組成物。
- 前記タンパク質が、VEGFアンタゴニストである、請求項1〜19のいずれか一項に記載の液体組成物。
- 前記VEGFアンタゴニストが、アフリベルセプトである、請求項21に記載の液体組成物。
- 硝子体内投与用である、請求項22に記載の液体組成物。
- 請求項23に記載の液体組成物を含む、硝子体内投与用注射剤。
- 以下を含む、液体組成物
(1)30mg/ml〜50mg/mlのアフリベルセプト;
(2)pH5.2〜7.2の緩衝液;
(3)安定剤;及び
(4)0.01〜0.1%(w/v)の界面活性剤、
であって、前記緩衝液は、1〜20mMリン酸ナトリウム、1〜20mMヒスチジン、又はそれらの組合せであり、
かつ前記安定剤は、塩化ナトリウムを含まない、液体組成物。 - 安定剤が、5〜12%(w/v)トレハロース、5〜12%(w/v)スクロース、及び2〜7%(w/v)マンニトールからなる群から選択される少なくとも1つを含む、請求項25に記載の液体組成物。。
- 安定剤が、5〜12%(w/v)スクロースを含む、請求項26に記載の液体組成物。
- 硝子体内投与用である、請求項25〜27のいずれか一項に記載の液体組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022128071A JP2022166159A (ja) | 2017-12-22 | 2022-08-10 | Vegfアンタゴニストを含む液体組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170178693 | 2017-12-22 | ||
KR10-2017-0178693 | 2017-12-22 | ||
PCT/KR2018/016156 WO2019124946A1 (ko) | 2017-12-22 | 2018-12-18 | Vegf 길항제를 포함하는 액상 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022128071A Division JP2022166159A (ja) | 2017-12-22 | 2022-08-10 | Vegfアンタゴニストを含む液体組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021508687A true JP2021508687A (ja) | 2021-03-11 |
Family
ID=66994837
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020534166A Pending JP2021508687A (ja) | 2017-12-22 | 2018-12-18 | Vegfアンタゴニストを含む液体組成物 |
JP2022128071A Pending JP2022166159A (ja) | 2017-12-22 | 2022-08-10 | Vegfアンタゴニストを含む液体組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022128071A Pending JP2022166159A (ja) | 2017-12-22 | 2022-08-10 | Vegfアンタゴニストを含む液体組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200390693A1 (ja) |
EP (1) | EP3730126A4 (ja) |
JP (2) | JP2021508687A (ja) |
KR (2) | KR20230021164A (ja) |
CN (1) | CN111556744B (ja) |
AU (1) | AU2018388301B2 (ja) |
BR (1) | BR112020012399A2 (ja) |
CA (2) | CA3085158C (ja) |
IL (1) | IL275238B2 (ja) |
TW (1) | TW202023603A (ja) |
WO (1) | WO2019124946A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019265005A1 (en) | 2018-05-10 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
CN116056688A (zh) * | 2020-07-24 | 2023-05-02 | 盼展生物技术有限公司 | 眼用液体组合物 |
JP2023535985A (ja) * | 2020-07-31 | 2023-08-22 | セルトリオン インク | 安定した薬剤学的製剤 |
TWI831202B (zh) * | 2022-05-13 | 2024-02-01 | 新源生物科技股份有限公司 | 血管內皮生長因子受體融合蛋白醫藥組合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016208989A1 (en) * | 2015-06-23 | 2016-12-29 | Alteogen, Inc. | A stable liquid formulation of fusion protein with igg fc domain |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614134B (zh) * | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
CA2654510C (en) * | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
AU2012202859B2 (en) * | 2006-06-16 | 2014-12-04 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
CN103816115B (zh) * | 2010-08-31 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
AU2012326171B2 (en) * | 2011-10-18 | 2017-03-09 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US9308355B2 (en) * | 2012-06-01 | 2016-04-12 | Surmodies, Inc. | Apparatus and methods for coating medical devices |
EP3744345B1 (en) * | 2013-03-13 | 2022-02-09 | F. Hoffmann-La Roche AG | Antibody formulations |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
JP7112327B2 (ja) * | 2015-12-29 | 2022-08-03 | アウトルック セラピューティクス,インコーポレイティド | ベバシズマブの緩衝された製剤 |
US11135266B2 (en) * | 2016-11-21 | 2021-10-05 | Just-Evotec Biologics, Inc. | Aflibercept formulations and uses thereof |
AU2019265005A1 (en) * | 2018-05-10 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
-
2018
- 2018-12-18 CA CA3085158A patent/CA3085158C/en active Active
- 2018-12-18 BR BR112020012399-4A patent/BR112020012399A2/pt active Search and Examination
- 2018-12-18 CA CA3189025A patent/CA3189025A1/en active Pending
- 2018-12-18 EP EP18893272.7A patent/EP3730126A4/en active Pending
- 2018-12-18 AU AU2018388301A patent/AU2018388301B2/en active Active
- 2018-12-18 KR KR1020237003082A patent/KR20230021164A/ko not_active Application Discontinuation
- 2018-12-18 CN CN201880082733.0A patent/CN111556744B/zh active Active
- 2018-12-18 IL IL275238A patent/IL275238B2/en unknown
- 2018-12-18 WO PCT/KR2018/016156 patent/WO2019124946A1/ko unknown
- 2018-12-18 JP JP2020534166A patent/JP2021508687A/ja active Pending
- 2018-12-18 US US16/770,858 patent/US20200390693A1/en active Pending
- 2018-12-18 KR KR1020207017668A patent/KR102494021B1/ko active IP Right Grant
-
2019
- 2019-06-21 TW TW108121726A patent/TW202023603A/zh unknown
-
2022
- 2022-08-10 JP JP2022128071A patent/JP2022166159A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016208989A1 (en) * | 2015-06-23 | 2016-12-29 | Alteogen, Inc. | A stable liquid formulation of fusion protein with igg fc domain |
Also Published As
Publication number | Publication date |
---|---|
US20200390693A1 (en) | 2020-12-17 |
CA3189025A1 (en) | 2019-06-27 |
WO2019124946A1 (ko) | 2019-06-27 |
AU2018388301A1 (en) | 2020-07-02 |
IL275238B1 (en) | 2023-08-01 |
CN111556744B (zh) | 2023-12-29 |
KR20200084897A (ko) | 2020-07-13 |
CA3085158C (en) | 2023-04-04 |
IL275238B2 (en) | 2023-12-01 |
EP3730126A1 (en) | 2020-10-28 |
KR102494021B1 (ko) | 2023-02-06 |
CA3085158A1 (en) | 2019-06-27 |
TW202023603A (zh) | 2020-07-01 |
IL275238A (en) | 2020-07-30 |
EP3730126A4 (en) | 2021-11-03 |
AU2018388301B2 (en) | 2022-02-17 |
KR20230021164A (ko) | 2023-02-13 |
JP2022166159A (ja) | 2022-11-01 |
CN111556744A (zh) | 2020-08-18 |
BR112020012399A2 (pt) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021508687A (ja) | Vegfアンタゴニストを含む液体組成物 | |
CA2903587C (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
KR101808234B1 (ko) | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 | |
Nakatani et al. | Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice | |
US20220054586A1 (en) | Liquid composition comprising protein | |
KR20170088927A (ko) | 골수형성이상 증후군 및 철적혈모구 빈혈을 치료하기 위한 방법 | |
EA027325B1 (ru) | Составы этанерцепта, стабилизированные ксилитом | |
KR20090008459A (ko) | Rage 융합 단백질, 제제 및 이의 사용 방법 | |
JP2023502501A (ja) | 眼内血管新生のための長時間作用型vegf阻害剤 | |
KR102461210B1 (ko) | Uti 융합 단백질 | |
JP2022514689A (ja) | 補体因子iおよび補体因子i補因子、それらをコードするベクターおよび治療的使用 | |
EP3775267A2 (en) | Novel angiopoietin 2, vegf dual antagonists | |
WO2023022968A2 (en) | Compositions and methods for treating renal diseases or conditions | |
JP2023528117A (ja) | 単一アームActRIIAおよびActRIIBヘテロ多量体および腎臓疾患または状態を処置するための方法 | |
KR20220050637A (ko) | Vegf 길항제를 포함하는 신규 제형 | |
WO2017187319A1 (en) | Nope for treatment of pathological muscle loss and weakness | |
NZ751498B2 (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
NZ751498A (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200717 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200717 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20201228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220810 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220810 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220823 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220920 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220927 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20221104 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20221108 |